Morgan Lewis and Marathon Capital advised Ashtrom Renewable Energy. Allen & Overy advised Stonehenge Capital. Paul Hastings LLP advised the lead arrangers and joint bookrunners. Ashtrom...
Ashtrom Renewable Energy’s $270 Million Green Solar Project
Swift Current Energy’s $779 Million Double Black Diamond Solar Project Financing
Vinson & Elkins and Husch Blackwell advised Swift Current Energy, and Paul Hastings advised the lenders. Swift Current Energy announced that it has closed project financing...
Neurogene’s Merger with Neoleukin
Gibson Dunn & Crutcher LLP is serving as legal counsel to Neurogene Inc. and Fenwick & West LLP is serving as legal counsel to Neoleukin Therapeutics,...
Spearmint’s $200 Million Term Loan Facility
Paul Hastings represented Spearmint as borrower and its subsidiaries as guarantors. Holland and Knight served as legal counsel for Aiga. Spearmint Energy announced the close of a...
Day One Biopharmaceuticals’ $150 Million Public Offering
Fenwick represented Day One Biopharmaceuticals, Inc. on the offering, while Cooley LLP represented the underwriters. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company focused...
Morphic Therapeutic’s $276 Million Public Offering
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
The Arena Group’s Acquisition of Digital Assets from a360Media
Fenwick represented The Arena Group on the deal. The Arena Group (NYSE American: AREN), a tech-powered media company home to more than 240 brands, including Sports...
Idera Pharmaceuticals’ Acquisition of Aceragen
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Castlight Health’s $370 Million Combination with Vera Whole Health
Fenwick & West advised Castlight Health on the deal, while Kirkland & Ellis advised Vera Whole Health. Castlight Health (NYSE: CSLT), a leading healthcare data and...
DICE Therapeutics’ $204 Million Initial Public Offering
Fenwick & West advised DICE Therapeutics on the deal. DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of...
Leeward Renewable Energy Operations’ $375 Million Green Bond Offering
Shearman & Sterling advised Leeward Renewable Energy Operations, while Latham & Watkins represented the initial purchasers in the offering. Leeward Renewable Energy Operations, a wholly owned...